一、行情回顾 市场全天震荡调整，创业板指领跌。创新药概念逆势大涨，睿智医药、海南海药、哈三联等多股涨停。猪肉、鸡肉股拉升，巨星农牧、湘佳股份封板。银行 股继续走强，杭州银行、成都银行创历史新高。下跌方面，高位股集体大跌，王子新材等多股跌停。个股跌多涨少，沪深京三市超4100股飘绿，今日成交 1.16万亿。 根据渤海证券统计，本周多款创新药获批上市，包括恒瑞医药的瑞康曲妥珠单抗、磷罗拉匹坦帕洛诺司琼、苹果酸法米替尼，复星医药的枸橼酸伏维西利、 芦沃美替尼，百济神州的泽尼达妥单抗，泽璟制药的盐酸吉卡昔替尼等，同时美国关税政策边际变化带动 CXO 板块快速反弹。 2025年美国临床肿瘤学会（ASCO）即将于当地时间5月30日至6月3日在美国芝加哥召开。 | 股票名称 | | 最新价 = | 涨跌幅 = | 涨停时间 = | 换手率 = | 流通市值 = | | | --- | --- | --- | --- | --- | --- | --- | --- | | 华森制药 | 4天4板 | 20.63 | +10.03% | 09:32:48 | 4.42% | 63.72亿 | 公司旗下5个产品完 美拉唑碳酸氢钠 ...

智通财经5月30日电，创新药概念股盘中持续走强，万邦德、康弘药业、千红制药、华森制药、哈三 联、联化科技、海南海药、华纳药厂、睿智医药等10余股涨停，舒泰神、科兴制药、冠昊生物等涨超 10%。 创新药概念股持续走高 万邦德等10余股涨停 ...

Group 1 - The core point of the article is the significant stock price increases of several pharmaceutical companies following the approval of 11 innovative drugs by the National Medical Products Administration on May 29 [1] Group 2 - Harbin Pharmaceutical Group (哈三联) reached the daily limit increase in stock price [1] - Companies such as Ruizhi Pharmaceutical (睿智医药), Xinnowei (新诺威), Hainan Haiyao (海南海药), and Huasen Pharmaceutical (华森制药) saw stock price increases of over 5% [1] - Other companies including Fosun Pharma (复星医药), Yipinhong (一品红), Haiwang Biological (海王生物), and Northeast Pharmaceutical (东北制药) also experienced stock price increases [1]

Market Overview - The three major A-share indices collectively adjusted in the morning session, with the Shanghai Composite Index down 0.30%, the Shenzhen Component Index down 0.71%, and the ChiNext Index down 1.28% [1] - The total market turnover for the half-day was 661 billion, a decrease of 1 billion compared to the previous day, with 2,600 stocks in the market showing losses [1] Sector Performance - The controllable nuclear fusion, gaming, and beverage manufacturing sectors led the gains, while the innovative drug sector experienced the largest declines [2] - Notable stocks in the controllable nuclear fusion sector included Haohan Huadong (301137), Xue Ren Co., Ltd. (002639), and Rongfa Nuclear Power (002366), all hitting the daily limit [2] - Gaming stocks also performed well, with Youzu Network (002174) reaching the daily limit [2] - Beverage manufacturing stocks rebounded, with Junyao Health (605388) and Kuaijishan (601579) hitting the daily limit [2] - The autonomous driving sector showed strength, with Jinjiang Online (600650), Tongda Electric (603390), and Longzhou Co., Ltd. (002682) all reaching the daily limit [2] - The innovative drug sector saw significant declines, with Haichen Pharmaceutical (300584) dropping over 10%, and Hainan Hai Pharmaceutical (000566) and San Sheng Guojian also experiencing notable losses [2] Hotspot Overview - The nuclear power sector was highlighted as the strongest market focus, with 11 stocks hitting the daily limit and 5 stocks achieving consecutive limit-ups, including Shangwei Co., Ltd. and Zhongchao Holdings (002471) [7] - The military industry sector also saw 11 stocks hitting the daily limit, with 5 stocks achieving consecutive limit-ups [8] - The artificial intelligence sector had 9 stocks hitting the daily limit, with one stock achieving consecutive limit-ups [9] Key Developments - The controllable nuclear fusion sector is gaining attention following U.S. President Trump's recent executive orders aimed at launching the construction of 10 large nuclear power plants by 2030 and quadrupling the nuclear power capacity by 2050 [10] - The IP economy is also gaining traction, with stocks like Youzu Network and others seeing significant interest, particularly following the recent rise in the market value of Pop Mart in Hong Kong [11] - The autonomous driving sector is attracting capital, with recent funding rounds for companies like Jiushi Intelligent and New Stone Technology, indicating strong investor interest in this area [12]

Group 1: Clinical Trials and Results - The company is conducting Phase IIa clinical trials for the drug Paiengabin, with 12 subjects enrolled in the first dose group, showing a 25.47% reduction in seizure frequency over 28 days compared to baseline [5] - In Phase I clinical studies, Paiengabin demonstrated linear pharmacokinetics across doses of 2.5-25 mg, with no serious adverse events reported [3][4] - The Phase IIa trial results are still blinded, and final efficacy data will be available post-unblinding [5] Group 2: Drug Characteristics and Comparison - Paiengabin is a KCNQ potassium channel agonist, designed to overcome the limitations of the previously marketed drug Retigabine, which was withdrawn due to safety concerns [6] - Non-clinical studies indicate that Paiengabin has superior chemical stability and better distribution in the brain compared to Retigabine, enhancing its efficacy against epilepsy [7] Group 3: Future Development and Market Strategy - The company plans to explore expanding Paiengabin's indications based on Phase II clinical outcomes and market demand, potentially including severe depression caused by KCNQ mutations [9] - The patent for Paiengabin is held by the Shanghai Institute of Materia Medica, with exclusive rights for clinical development and commercialization in mainland China [9] - The company is considering international rights transfer for Paiengabin, depending on the outcomes of the Phase II trials [9] Group 4: Fluorofenone Clinical Trials - Fluorofenone's Phase I clinical trials have shown good safety and tolerability in healthy subjects, with adverse events primarily mild to moderate [10] - The Phase II mid-analysis for Fluorofenone included 156 subjects, with a 55.6% reduction in Ishak fibrosis scores after 48 weeks [11] - The company anticipates entering Phase III clinical trials for Fluorofenone in the second half of 2025, with the drug included in the list of breakthrough therapies by the National Medical Products Administration [11]

Core Viewpoint - Hainan Haiyao Co., Ltd. is accelerating its transformation into an innovative R&D pharmaceutical manufacturer, focusing on the development of new drugs and leveraging the Hainan Free Trade Port policies to enhance its product pipeline and contribute to public health [2][3][4]. Group 1: Innovation and R&D - The company has made significant progress with two new drugs, Fluorofenidone and Paenangin, marking a shift towards innovative drug development [2]. - Hainan Haiyao is committed to developing strategic emerging industries, establishing platforms for large molecule CDMO and national-level testing, and expanding its pipeline for rare and prevalent diseases [2][4]. - The company has increased its R&D investment and has achieved notable success in the generic drug sector, with 34 specifications of 16 products passing consistency evaluations since 2021 [4]. Group 2: International Collaboration and Product Introduction - Hainan Haiyao is actively introducing high-quality foreign products to enrich its product pipeline and enhance medical service levels, establishing partnerships with international biopharmaceutical companies [3]. - The company is negotiating with several global pharmaceutical giants to select products with advanced technology and significant market potential for introduction into China [3]. Group 3: Talent Development and Research Infrastructure - Hainan Haiyao has recruited over 90 high-level R&D talents from prestigious universities both domestically and internationally, establishing a new drug R&D system that integrates production, learning, and research [3]. - The company has set up specialized teams for overseas product introduction and technical analysis to accelerate the integration of advanced biopharmaceutical products [3].

Core Insights - Hainan Haiyao has made significant progress in the development of two innovative drugs: Fluorofenidone capsules for organ fibrosis diseases and Paenagabin tablets for neurological disorders [2][3] - Fluorofenidone capsules have been included in the National Medical Products Administration's list of breakthrough therapies as of February 2025, with Phase I clinical trials confirming safety and tolerability, and Phase II trials achieving primary endpoints [2] - Paenagabin tablets, a new generation KCNQ potassium channel agonist, have shown excellent safety and tolerability in Phase I trials, with ongoing Phase IIa studies [2] Company Strategy - Hainan Haiyao is committed to enhancing its strategic layout in emerging industries, focusing on the development of innovative drugs and increasing R&D investment [3] - The company aims to transform from a "generic-innovative combination" model to an "innovation-driven" development approach, positioning itself as a benchmark for innovative development in Hainan Free Trade Port [3] - Future plans include leveraging the advantages of Hainan Free Trade Port's biopharmaceutical policies to introduce high-end foreign medical products and promote the company's innovative products internationally [3]

海南海药股份有限公司 关于独立董事辞职的公告 魏玉林先生担任公司独立董事期间，恪尽职守、勤勉尽责，并积极为公司发 展建言献策，公司及董事会对魏玉林先生在任职期间为公司作出的贡献致以衷心 的感谢。 特此公告 证券代码：000566 证券简称：海南海药 公告编号：2025-040 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）董事会于近日收到独立董事魏 玉林先生的辞职报告，其因个人原因申请辞去公司独立董事及董事会相应专门委 员会职务。辞职后，魏玉林先生将不再担任海南海药股份有限公司任何职务。截 至本公告披露日，魏玉林先生未持有公司股份。 魏玉林先生的辞职将导致公司独立董事人数少于董事会成员的三分之一，因 此辞职申请将在公司股东大会选举产生新任独立董事后生效。在此期间，魏玉林 先生仍应继续履行其作为独立董事及各董事会专门委员会的相关职责。根据《中 华人民共和国公司法》《深圳证券交易所上市公司规范运作指引》和《公司章程》 等有关规定，公司董事会将按照法定程序尽快完成新任独立董事的补选工作。 董 事 会 二〇二五年五月二十二日 海 ...

Group 1 - BYD reported August sales of 174,915 new energy vehicles, a year-on-year increase of 184.84% [1] - Cumulative sales from January to August reached 978,795 units, representing a year-on-year growth of 267.31% [1] - The company sold 5,092 new energy passenger vehicles overseas in August [1] Group 2 - Zhongke Electric's subsidiary plans to establish a joint venture with Chongqing Fudi for the production of anode materials, with a registered capital of 1 billion RMB [2] - Zhongke Electric's subsidiary will contribute 650 million RMB, while Chongqing Fudi will contribute 350 million RMB [2] Group 3 - Yuyuan Group intends to transfer 13% of its shares in Jinhuijiu for approximately 1.937 billion RMB, reducing its stake to 25% [3] - The company plans to further reduce its holdings by more than 5% within the next six months [3] Group 4 - Lizhu Group's recombinant COVID-19 fusion protein vaccine has been included in the emergency use for sequential booster immunization [4] Group 5 - Guanghui Energy plans to repurchase shares worth between 800 million and 1 billion RMB to support employee stock ownership plans [5] Group 6 - Cambrian has launched four cloud-based intelligent chips, although mass sales will require a longer time frame and initial technical service investments [7] Group 7 - LePu Medical has received approval from the China Securities Regulatory Commission for the issuance of Global Depositary Receipts (GDRs) and listing on the Swiss Stock Exchange [9] - The GDR issuance will correspond to no more than 180,458,875 new A-shares [9] Group 8 - Fushi Holdings' subsidiary has entered into an exclusive advertising agency cooperation with the Central Radio and Television Station's automotive channel for three years [10] Group 9 - Guangzhou Port's container throughput in August was 1.981 million TEUs, a year-on-year increase of 2.4% [11] - The total cargo throughput for August was 44.788 million tons, a decrease of 0.6% [11] Group 10 - Ningbo Port expects to complete a container throughput of 3.58 million TEUs in August, a year-on-year increase of 10.2% [12] - The total cargo throughput is projected to decline by 3.0% [12] Group 11 - Ming Tai Aluminum reported a 7% year-on-year decrease in aluminum plate and strip sales in August, while aluminum profile sales increased by 47% [13] Group 12 - Electric Power Investment plans to invest in multiple wind and solar projects, with total static investments of 1.585 billion RMB for wind and 538 million RMB for solar [14] Group 13 - Northeast Pharmaceutical has signed a cooperation agreement with MedAbome for the development of the MAb11-22.1 antibody project [19] Group 14 - New Five Feng plans to acquire equity in Tianxin Seed Industry and several other companies for a total price of approximately 2.208 billion RMB [26] Group 15 - Sumeida's subsidiary plans to transfer 100% equity of eight photovoltaic power station project companies, with an estimated transaction value of 657 million RMB [27] Group 16 - *ST Tongzhou intends to acquire 51% equity in Tongtaiwei, fulfilling the capital contribution obligation of 10.2 million RMB [29] Group 17 - Tianyin Holdings' subsidiary plans to invest 120 million RMB in Xundong Xintong to acquire 40% equity [30] Group 18 - Hainan Haiyao plans to publicly transfer 43% equity in Shanghai Lishengte to attract new investors [31] Group 19 - New Asia Process plans to transfer 7.76% of its shares to Xiangcai New Materials at a price of 5.274 RMB per share [32] Group 20 - Lanwei Medical plans to raise no more than 664 million RMB through a private placement for provincial laboratory construction projects [34] Group 21 - Lida New Materials plans to issue convertible bonds to raise no more than 300 million RMB for a new aluminum material project [35] Group 22 - Gekewei has successfully launched its 12-inch CIS integrated circuit project, achieving over 95% yield [51] Group 23 - Baijin Medical's tricuspid valve ring product has received registration approval [52] Group 24 - Shanghai Pharmaceuticals has received approval to initiate Phase I clinical trials for a recombinant anti-CD20 humanized monoclonal antibody [53] Group 25 - Junda Co. has increased the production capacity of its solar cell production base project from 8GW to 10GW [54]

Core Viewpoint - The article highlights the expansion of Chinese companies into international markets, particularly in regions like Brazil, Hungary, and the Middle East, showcasing significant investments and strategic partnerships aimed at enhancing global presence and operational capabilities [3][8][10]. Group 1: Company Expansions and Investments - Meituan has signed a $1 billion investment agreement to introduce its food delivery service Keeta into the Brazilian market, aiming to build a nationwide delivery network over the next five years [8]. - BYD has announced the establishment of its European headquarters in Hungary, with a total investment of approximately 100 billion HUF (around €248 million), which is expected to create 2,000 jobs [9]. - Mijia Ice City has signed a memorandum to invest at least 4 billion RMB in Brazil over the next 3-5 years, planning to open its first store in the country this year [8]. - Great Wall Motors plans to establish a research and development center and manufacturing base in Brazil, with an initial production capacity of 50,000 vehicles per year [8]. - Baidu's autonomous driving service, "萝卜快跑," is expanding into Switzerland, Turkey, and Japan, with plans for large-scale testing and deployment [10]. Group 2: Financial Performance and Market Trends - Tencent reported a 23% year-on-year increase in international gaming revenue for Q1 2025, reaching 16.6 billion RMB, driven by popular titles like PUBG MOBILE [14]. - The global in-app purchase revenue for short video applications reached nearly $700 million in Q1 2025, marking a significant increase compared to the previous year [18]. - Alibaba's logistics arm, Cainiao, achieved annual revenue exceeding 100 billion RMB, driven by international logistics growth [15]. Group 3: Strategic Partnerships and Collaborations - Hainan Haiyao signed a strategic cooperation framework agreement with Malaysia's Aikang International Group to enhance collaboration in the health sector [17]. - TikTok is under scrutiny by the EU for potential violations of the Digital Services Act regarding advertising transparency [14]. - The Australian Trade Minister expressed a desire to expand trade relations with China, emphasizing the importance of the Chinese market [19].